InstitutionMD Anderson
DepartmentExperimental Radiation Oncology
Address6565 MD Anderson Blvd
Houston TX 77030
vCardDownload vCard

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Lulla AR, Akli S, Karakas C, Caruso JA, Warma LD, Fowlkes NW, Rao X, Wang J, Hunt KK, Watowich SS, Keyomarsi K. Neutrophil Elastase Remodels Mammary Tumors to Facilitate Lung Metastasis. Mol Cancer Ther. 2024 Apr 02; 23(4):492-506. PMID: 37796181; PMCID: PMC10987287.
      Citations: 1     Fields:    
    2. Patel B, Zhou Y, Babcock RL, Ma F, Zal MA, Kumar D, Medik YB, Kahn LM, Pineda JE, Park EM, Schneider SM, Tang X, Raso MG, Jeter CR, Zal T, Clise-Dwyer K, Keyomarsi K, Giancotti FG, Colla S, Watowich SS. STAT3 protects hematopoietic stem cells by preventing activation of a deleterious autocrine type-I interferon response. Leukemia. 2024 May; 38(5):1143-1155. PMID: 38467768.
      Citations:    Fields:    Translation:AnimalsCells
    3. Adesoye T, Tripathy D, Hunt KK, Keyomarsi K. Exploring Novel Frontiers: Leveraging STAT3 Signaling for Advanced Cancer Therapeutics. Cancers (Basel). 2024 Jan 24; 16(3). PMID: 38339245; PMCID: PMC10854592.
    4. Lee H, Horbath A, Kondiparthi L, Meena JK, Lei G, Dasgupta S, Liu X, Zhuang L, Koppula P, Li M, Mahmud I, Wei B, Lorenzi PL, Keyomarsi K, Poyurovsky MV, Olszewski K, Gan B. Cell cycle arrest induces lipid droplet formation and confers ferroptosis resistance. Nat Commun. 2024 01 02; 15(1):79. PMID: 38167301; PMCID: PMC10761718.
      Citations: 1     Fields:    Translation:HumansCells
    5. DiPeri TP, Evans KW, Raso MG, Zhao M, Rizvi YQ, Zheng X, Wang B, Kirby BP, Kong K, Kahle M, Yap TA, Dumbrava EE, Ajani JA, Fu S, Keyomarsi K, Meric-Bernstam F. Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers. Clin Cancer Res. 2023 11 01; 29(21):4385-4398. PMID: 37279095; PMCID: PMC10618648.
      Citations: 1     Fields:    Translation:HumansAnimals
    6. Navarro-Yepes J, Kettner NM, Rao X, Bishop CS, Bui TN, Wingate HF, Singareeka Raghavendra A, Wang Y, Wang J, Sahin AA, Meric-Bernstam F, Hunt KK, Damodaran S, Tripathy D, Keyomarsi K. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers. Cancer Res. 2023 10 02; 83(19):3264-3283. PMID: 37384539; PMCID: PMC10592446.
      Citations: 1     Fields:    Translation:HumansAnimals
    7. Wingate HF, Keyomarsi K. Distinct Mechanisms of Resistance to CDK4/6 Inhibitors Require Specific Subsequent Treatment Strategies: One Size Does Not Fit All. Cancer Res. 2023 10 02; 83(19):3165-3167. PMID: 37779425.
      Citations:    Fields:    Translation:Humans
    8. Haddad TC, Suman VJ, D'Assoro AB, Carter JM, Giridhar KV, McMenomy BP, Santo K, Mayer EL, Karuturi MS, Morikawa A, Marcom PK, Isaacs CJ, Oh SY, Clark AS, Mayer IA, Keyomarsi K, Hobday TJ, Peethambaram PP, O'Sullivan CC, Leon-Ferre RA, Liu MC, Ingle JN, Goetz MP. Evaluation of Alisertib Alone or Combined With Fulvestrant in Patients With Endocrine-Resistant Advanced Breast Cancer: The Phase 2 TBCRC041 Randomized Clinical Trial. JAMA Oncol. 2023 06 01; 9(6):815-824. PMID: 36892847; PMCID: PMC9999287.
      Citations: 1     Fields:    Translation:HumansCTClinical Trials
    9. Nguyen TDT, Wang Y, Bui TN, Lazcano R, Ingram DR, Yi M, Vakulabharanam V, Luo L, Pina MA, Karakas C, Li M, Kettner NM, Somaiah N, Hougton PJ, Mawlawi O, Lazar AJ, Hunt KK, Keyomarsi K. Sequential Targeting of Retinoblastoma and DNA Synthesis Pathways Is a Therapeutic Strategy for Sarcomas That Can Be Monitored in Real Time. Cancer Res. 2023 03 15; 83(6):939-955. PMID: 36603130; PMCID: PMC10023441.
      Citations:    Fields:    Translation:Humans
    10. Fu S, Yao S, Yuan Y, Previs RA, Elias AD, Carvajal RD, George TJ, Yuan Y, Yu L, Westin SN, Xing Y, Dumbrava EE, Karp DD, Piha-Paul SA, Tsimberidou AM, Ahnert JR, Takebe N, Lu K, Keyomarsi K, Meric-Bernstam F. Multicenter Phase II Trial of the WEE1 Inhibitor Adavosertib in Refractory Solid Tumors Harboring CCNE1 Amplification. J Clin Oncol. 2023 03 20; 41(9):1725-1734. PMID: 36469840; PMCID: PMC10489509.
      Citations: 5     Fields:    Translation:HumansCTClinical Trials
    11. Li M, Tsavachidis S, Wang F, Bui T, Nguyen TDT, Luo L, Multani AS, Bondy ML, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E deregulates DNA replication and damage repair to promote genomic instability in breast cancer. Oncogene. 2022 Dec; 41(50):5331-5346. PMID: 36344674; PMCID: PMC9742291.
      Citations:    Fields:    Translation:HumansCells
    12. Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res. 2022 09 02; 82(17):3088-3101. PMID: 35771632; PMCID: PMC9444962.
      Citations:    Fields:    
    13. Luo L, Keyomarsi K. PARP inhibitors as single agents and in combination therapy: the most promising treatment strategies in clinical trials for BRCA-mutant ovarian and triple-negative breast cancers. Expert Opin Investig Drugs. 2022 Jun; 31(6):607-631. PMID: 35435784; PMCID: PMC9296104.
      Citations: 1     Fields:    Translation:Humans
    14. Ha MJ, Singareeka Raghavendra A, Kettner NM, Qiao W, Damodaran S, Layman RM, Hunt KK, Shen Y, Tripathy D, Keyomarsi K. Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting: A large institutional study. Int J Cancer. 2022 06 15; 150(12):2025-2037. PMID: 35133007; PMCID: PMC9018572.
      Citations:    Fields:    Translation:Humans
    15. Karakas C, Francis AM, Ha MJ, Wingate HF, Meena RA, Yi M, Rasaputra KS, Barrera AMG, Arun B, Do KA, Sahin A, Keyomarsi K, Hunt KK. Cytoplasmic Cyclin E Expression Predicts for Response to Neoadjuvant Chemotherapy in Breast Cancer. Ann Surg. 2021 08 01; 274(2):e150-e159. PMID: 31436549; PMCID: PMC7031042.
      Citations: 3     Fields:    Translation:Humans
    16. Lulla AR, Akli S, Karakas C, Ha MJ, Fowlkes NW, Mitani Y, Bui T, Wang J, Rao X, Hunt KK, Meijer L, El-Naggar AK, Keyomarsi K. LMW cyclin E and its novel catalytic partner CDK5 are therapeutic targets and prognostic biomarkers in salivary gland cancers. Oncogenesis. 2021 May 14; 10(5):40. PMID: 33990543; PMCID: PMC8121779.
    17. Chen X, Yang D, Carey JPW, Karakas C, Albarracin C, Sahin AA, Arun BK, Guray Durak M, Li M, Kohansal M, Bui TN, Ha MJ, Hunt KK, Keyomarsi K. Targeting Replicative Stress and DNA Repair by Combining PARP and Wee1 Kinase Inhibitors Is Synergistic in Triple Negative Breast Cancers with Cyclin E or BRCA1 Alteration. Cancers (Basel). 2021 Apr 01; 13(7). PMID: 33916118; PMCID: PMC8036262.
      Citations: 2     
    18. Knudsen ES, Shapiro GI, Keyomarsi K. Selective CDK4/6 Inhibitors: Biologic Outcomes, Determinants of Sensitivity, Mechanisms of Resistance, Combinatorial Approaches, and Pharmacodynamic Biomarkers. Am Soc Clin Oncol Educ Book. 2020 May; 40:115-126. PMID: 32421454; PMCID: PMC7306922.
      Citations: 5     Fields:    Translation:HumansAnimals
    19. Johnston SJ, Syed BM, Parks RM, Caruso JA, Green AR, Ellis IO, Hunt KK, Karakas C, Keyomarsi K, Cheung KL, Monteiro CJ. Cytoplasmic Cyclin E Is an Independent Marker of Aggressive Tumor Biology and Breast Cancer-Specific Mortality in Women over 70 Years of Age. Cancers (Basel). 2020 Mar 18; 12(3). PMID: 32197318; PMCID: PMC7140020.
      Citations: 2     
    20. Mull BB, Livingston JA, Patel N, Bui T, Hunt KK, Keyomarsi K. Specific, reversible G1 arrest by UCN-01 in vivo provides cytostatic protection of normal cells against cytotoxic chemotherapy in breast cancer. Br J Cancer. 2020 03; 122(6):812-822. PMID: 31942030; PMCID: PMC7078276.
      Citations: 1     Fields:    Translation:HumansAnimals
    21. Kettner NM, Vijayaraghavan S, Durak MG, Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, Carey JPW, Chen X, Eckols TK, Raghavendra AS, Ibrahim NK, Karuturi MS, Watowich SS, Sahin A, Tweardy DJ, Hunt KK, Tripathy D, Keyomarsi K. Combined Inhibition of STAT3 and DNA Repair in Palbociclib-Resistant ER-Positive Breast Cancer. Clin Cancer Res. 2019 07 01; 25(13):3996-4013. PMID: 30867218; PMCID: PMC6606366.
      Citations: 35     Fields:    Translation:HumansCells
    22. Caruso JA, Duong MT, Carey JPW, Hunt KK, Keyomarsi K. Low-Molecular-Weight Cyclin E in Human Cancer: Cellular Consequences and Opportunities for Targeted Therapies. Cancer Res. 2018 10 01; 78(19):5481-5491. PMID: 30194068; PMCID: PMC6168358.
      Citations: 19     Fields:    Translation:HumansAnimalsCells
    23. Chen X, Low KH, Alexander A, Jiang Y, Karakas C, Hess KR, Carey JPW, Bui TN, Vijayaraghavan S, Evans KW, Yi M, Ellis DC, Cheung KL, Ellis IO, Fu S, Meric-Bernstam F, Hunt KK, Keyomarsi K. Cyclin E Overexpression Sensitizes Triple-Negative Breast Cancer to Wee1 Kinase Inhibition. Clin Cancer Res. 2018 12 15; 24(24):6594-6610. PMID: 30181387; PMCID: PMC6317865.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    24. Fu S, Wang Y, Keyomarsi K, Meric-Bernstein F. Strategic development of AZD1775, a Wee1 kinase inhibitor, for cancer therapy. Expert Opin Investig Drugs. 2018 09; 27(9):741-751. PMID: 30102076.
      Citations: 21     Fields:    Translation:HumansAnimals
    25. Carey JPW, Keyomarsi K. Leveraging MYC as a therapeutic treatment option for TNBC. Oncoscience. 2018 May; 5(5-6):137-139. PMID: 30035166; PMCID: PMC6049306.
      Citations: 2     
    26. Xi Y, Shi J, Li W, Tanaka K, Allton KL, Richardson D, Li J, Franco HL, Nagari A, Malladi VS, Coletta LD, Simper MS, Keyomarsi K, Shen J, Bedford MT, Shi X, Barton MC, Kraus WL, Li W, Dent SYR. Histone modification profiling in breast cancer cell lines highlights commonalities and differences among subtypes. BMC Genomics. 2018 02 20; 19(1):150. PMID: 29458327; PMCID: PMC5819162.
      Citations: 25     Fields:    Translation:HumansCells
    27. Vijayaraghavan S, Moulder S, Keyomarsi K, Layman RM. Inhibiting CDK in Cancer Therapy: Current Evidence and Future Directions. Target Oncol. 2018 02; 13(1):21-38. PMID: 29218622.
      Citations: 33     Fields:    Translation:Humans
    28. Franco HL, Nagari A, Malladi VS, Li W, Xi Y, Richardson D, Allton KL, Tanaka K, Li J, Murakami S, Keyomarsi K, Bedford MT, Shi X, Li W, Barton MC, Dent SYR, Kraus WL. Enhancer transcription reveals subtype-specific gene expression programs controlling breast cancer pathogenesis. Genome Res. 2018 02; 28(2):159-170. PMID: 29273624; PMCID: PMC5793780.
      Citations: 61     Fields:    Translation:HumansCells
    29. Carey JPW, Karakas C, Bui T, Chen X, Vijayaraghavan S, Zhao Y, Wang J, Mikule K, Litton JK, Hunt KK, Keyomarsi K. Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer. Cancer Res. 2018 02 01; 78(3):742-757. PMID: 29180466; PMCID: PMC5811386.
      Citations: 48     Fields:    Translation:HumansAnimalsCells
    30. Doostan I, Karakas C, Kohansal M, Low KH, Ellis MJ, Olson JA, Suman VJ, Hunt KK, Moulder SL, Keyomarsi K. Cytoplasmic Cyclin E Mediates Resistance to Aromatase Inhibitors in Breast Cancer. Clin Cancer Res. 2017 Dec 01; 23(23):7288-7300. PMID: 28947566; PMCID: PMC5768442.
      Citations: 11     Fields:    Translation:HumansAnimalsCells
    31. Bashour SI, Doostan I, Keyomarsi K, Valero V, Ueno NT, Brown PH, Litton JK, Koenig KB, Karuturi M, Abouharb S, Tripathy D, Moulder-Thompson SL, Ibrahim NK. Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation. J Cancer. 2017; 8(11):2004-2009. PMID: 28819400; PMCID: PMC5559961.
      Citations: 6     
    32. Vijayaraghavan S, Karakas C, Doostan I, Chen X, Bui T, Yi M, Raghavendra AS, Zhao Y, Bashour SI, Ibrahim NK, Karuturi M, Wang J, Winkler JD, Amaravadi RK, Hunt KK, Tripathy D, Keyomarsi K. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers. Nat Commun. 2017 06 27; 8:15916. PMID: 28653662; PMCID: PMC5490269.
      Citations: 112     Fields:    Translation:HumansAnimalsCells
    33. Francis AM, Alexander A, Liu Y, Vijayaraghavan S, Low KH, Yang D, Bui T, Somaiah N, Ravi V, Keyomarsi K, Hunt KK. CDK4/6 Inhibitors Sensitize Rb-positive Sarcoma Cells to Wee1 Kinase Inhibition through Reversible Cell-Cycle Arrest. Mol Cancer Ther. 2017 09; 16(9):1751-1764. PMID: 28619757; PMCID: PMC5975955.
      Citations: 17     Fields:    Translation:HumansAnimalsCells
    34. Alexander A, Karakas C, Chen X, Carey JP, Yi M, Bondy M, Thompson P, Cheung KL, Ellis IO, Gong Y, Krishnamurthy S, Alvarez RH, Ueno NT, Hunt KK, Keyomarsi K. Cyclin E overexpression as a biomarker for combination treatment strategies in inflammatory breast cancer. Oncotarget. 2017 Feb 28; 8(9):14897-14911. PMID: 28107181; PMCID: PMC5362453.
      Citations: 17     Fields:    Translation:HumansCells
    35. Hunt KK, Karakas C, Ha MJ, Biernacka A, Yi M, Sahin AA, Adjapong O, Hortobagyi GN, Bondy M, Thompson P, Cheung KL, Ellis IO, Bacus S, Symmans WF, Do KA, Keyomarsi K. Cytoplasmic Cyclin E Predicts Recurrence in Patients with Breast Cancer. Clin Cancer Res. 2017 Jun 15; 23(12):2991-3002. PMID: 27881578; PMCID: PMC5441976.
      Citations: 23     Fields:    Translation:HumansCells
    36. Balaji K, Vijayaraghavan S, Diao L, Tong P, Fan Y, Carey JP, Bui TN, Warner S, Heymach JV, Hunt KK, Wang J, Byers LA, Keyomarsi K. AXL Inhibition Suppresses the DNA Damage Response and Sensitizes Cells to PARP Inhibition in Multiple Cancers. Mol Cancer Res. 2017 01; 15(1):45-58. PMID: 27671334; PMCID: PMC5215967.
      Citations: 42     Fields:    Translation:HumansCells
    37. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol. 2016 07; 186(7):1900-1912. PMID: 27182644; PMCID: PMC4929404.
      Citations: 22     Fields:    Translation:HumansAnimalsCells
    38. JavanMoghadam S, Weihua Z, Hunt KK, Keyomarsi K. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 2016 06 17; 15(12):1579-90. PMID: 27049344; PMCID: PMC4934046.
      Citations: 12     Fields:    Translation:HumansCells
    39. Lucenay KS, Doostan I, Karakas C, Bui T, Ding Z, Mills GB, Hunt KK, Keyomarsi K. Cyclin E Associates with the Lipogenic Enzyme ATP-Citrate Lyase to Enable Malignant Growth of Breast Cancer Cells. Cancer Res. 2016 04 15; 76(8):2406-18. PMID: 26928812; PMCID: PMC4873469.
      Citations: 30     Fields:    Translation:HumansCells
    40. Wang X, Jung YS, Jun S, Lee S, Wang W, Schneider A, Sun Oh Y, Lin SH, Park BJ, Chen J, Keyomarsi K, Park JI. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nat Commun. 2016 Feb 04; 7:10633. PMID: 26843124; PMCID: PMC4743006.
      Citations: 31     Fields:    Translation:HumansAnimalsCells
    41. Jabbour-Leung NA, Chen X, Bui T, Jiang Y, Yang D, Vijayaraghavan S, McArthur MJ, Hunt KK, Keyomarsi K. Sequential Combination Therapy of CDK Inhibition and Doxorubicin Is Synthetically Lethal in p53-Mutant Triple-Negative Breast Cancer. Mol Cancer Ther. 2016 04; 15(4):593-607. PMID: 26826118; PMCID: PMC4873336.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    42. Nanos-Webb A, Bui T, Karakas C, Zhang D, Carey JP, Mills GB, Hunt KK, Keyomarsi K. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene. 2016 05 12; 35(19):2428-40. PMID: 26279297; PMCID: PMC4856585.
      Citations: 10     Fields:    Translation:HumansAnimalsCells
    43. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Erratum to: Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015 Jun 25; 17:87. PMID: 26108797; PMCID: PMC4480452.
      Citations:    Fields:    
    44. Mitri Z, Karakas C, Wei C, Briones B, Simmons H, Ibrahim N, Alvarez R, Murray JL, Keyomarsi K, Moulder S. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Invest New Drugs. 2015 Aug; 33(4):890-4. PMID: 25947565.
      Citations: 25     Fields:    Translation:HumansCTClinical Trials
    45. Pickering CR, Bast RC, Keyomarsi K. How will we recruit, train, and retain physicians and scientists to conduct translational cancer research? Cancer. 2015 Mar 15; 121(6):806-16. PMID: 25355050; PMCID: PMC4352128.
      Citations: 7     Fields:    Translation:Humans
    46. Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67. PMID: 25195861; PMCID: PMC4362782.
      Citations: 16     Fields:    Translation:HumansAnimalsCells
    47. Wu SY, Yang X, Gharpure KM, Hatakeyama H, Egli M, McGuire MH, Nagaraja AS, Miyake TM, Rupaimoole R, Pecot CV, Taylor M, Pradeep S, Sierant M, Rodriguez-Aguayo C, Choi HJ, Previs RA, Armaiz-Pena GN, Huang L, Martinez C, Hassell T, Ivan C, Sehgal V, Singhania R, Han HD, Su C, Kim JH, Dalton HJ, Kovvali C, Keyomarsi K, McMillan NA, Overwijk WW, Liu J, Lee JS, Baggerly KA, Lopez-Berestein G, Ram PT, Nawrot B, Sood AK. 2'-OMe-phosphorodithioate-modified siRNAs show increased loading into the RISC complex and enhanced anti-tumour activity. Nat Commun. 2014 Mar 12; 5:3459. PMID: 24619206; PMCID: PMC4112501.
      Citations: 42     Fields:    Translation:HumansAnimalsCells
    48. Caruso JA, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A, Bondy M, Liu J, Hunt KK, Keyomarsi K. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2014; 16(6):3417. PMID: 25551582; PMCID: PMC4326485.
      Citations: 13     Fields:    Translation:HumansCells
    49. Caruso JA, Campana R, Wei C, Su CH, Hanks AM, Bornmann WG, Keyomarsi K. Indole-3-carbinol and its N-alkoxy derivatives preferentially target ERa-positive breast cancer cells. Cell Cycle. 2014; 13(16):2587-99. PMID: 25486199; PMCID: PMC4614451.
      Citations: 12     Fields:    Translation:HumansCells
    50. Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res. 2013 Sep 01; 73(17):5556-68. PMID: 23955388; PMCID: PMC3773499.
      Citations: 21     Fields:    Translation:HumansCells
    51. Murray MM, Bui T, Smith M, Bagheri-Yarmand R, Wingate H, Hunt KK, Keyomarsi K. Staurosporine is chemoprotective by inducing G1 arrest in a Chk1- and pRb-dependent manner. Carcinogenesis. 2013 Oct; 34(10):2244-52. PMID: 23722650; PMCID: PMC3786379.
      Citations: 3     Fields:    Translation:HumansCells
    52. Dutta P, Bui T, Bauckman KA, Keyomarsi K, Mills GB, Nanjundan M. EVI1 splice variants modulate functional responses in ovarian cancer cells. Mol Oncol. 2013 Jun; 7(3):647-68. PMID: 23517670; PMCID: PMC3805042.
      Citations: 21     Fields:    Translation:HumansCells
    53. Hunt KK, Wingate H, Yokota T, Liu Y, Mills GB, Zhang F, Fang B, Su CH, Zhang M, Yi M, Keyomarsi K. Elafin, an inhibitor of elastase, is a prognostic indicator in breast cancer. Breast Cancer Res. 2013 Jan 15; 15(1):R3. PMID: 23320734; PMCID: PMC3672770.
      Citations: 21     Fields:    Translation:HumansAnimalsCells
    54. Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 2012 Apr 01; 11(7):1468-76. PMID: 22441703; PMCID: PMC3350882.
      Citations: 13     Fields:    Translation:HumansCells
    55. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538. PMID: 22479189; PMCID: PMC3315462.
      Citations: 26     Fields:    Translation:HumansAnimalsCells
    56. Moghadam SJ, Hanks AM, Keyomarsi K. Breaking the cycle: An insight into the role of ERa in eukaryotic cell cycles. J Carcinog. 2011; 10:25. PMID: 22190867; PMCID: PMC3243079.
      Citations: 5     
    57. Nanos-Webb A, Jabbour NA, Multani AS, Wingate H, Oumata N, Meijer L, Hunt KK, Keyomarsi K, Galons H, Joseph B. Targeting low molecular weight cyclin E (LMW-E) in breast cancer. Breast Cancer Res Treat. 2012 Apr; 132(2):575-88. PMID: 21695458; PMCID: PMC3855283.
      Citations: 22     Fields:    Translation:HumansCells
    58. Valero V, Wingate H, Chada S, Liu Y, Palalon F, Mills G, Keyomarsi K, Hunt KK. MDA-7 results in downregulation of AKT concomitant with apoptosis and cell cycle arrest in breast cancer cells. Cancer Gene Ther. 2011 Jul; 18(7):510-9. PMID: 21546925; PMCID: PMC3875403.
      Citations: 5     Fields:    Translation:HumansCells
    59. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011 May 01; 71(9):3377-86. PMID: 21385896; PMCID: PMC3085722.
      Citations: 24     Fields:    Translation:HumansAnimals
    60. Keyomarsi K, Efuet ET, Bui TN. Semi-high throughput method of measuring proteasome inhibition in vitro and in cultured cells. Cell Biol Toxicol. 2011 Apr; 27(2):123-31. PMID: 20853140.
      Citations: 3     Fields:    Translation:AnimalsCells
    61. Caruso JA, Hunt KK, Keyomarsi K. The neutrophil elastase inhibitor elafin triggers rb-mediated growth arrest and caspase-dependent apoptosis in breast cancer. Cancer Res. 2010 Sep 15; 70(18):7125-36. PMID: 20823156; PMCID: PMC2940941.
      Citations: 17     Fields:    Translation:HumansCells
    62. Bagheri-Yarmand R, Biernacka A, Hunt KK, Keyomarsi K. Low molecular weight cyclin E overexpression shortens mitosis, leading to chromosome missegregation and centrosome amplification. Cancer Res. 2010 Jun 15; 70(12):5074-84. PMID: 20530685; PMCID: PMC2888821.
      Citations: 32     Fields:    Translation:HumansCells
    63. Bagheri-Yarmand R, Nanos-Webb A, Biernacka A, Bui T, Keyomarsi K. Cyclin E deregulation impairs mitotic progression through premature activation of Cdc25C. Cancer Res. 2010 Jun 15; 70(12):5085-95. PMID: 20530684; PMCID: PMC2946214.
      Citations: 16     Fields:    Translation:HumansCells
    64. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907. PMID: 20453888; PMCID: PMC2900397.
      Citations: 33     Fields:    Translation:HumansAnimalsCells
    65. Sun B, Wingate H, Swisher SG, Keyomarsi K, Hunt KK. Absence of pRb facilitates E2F1-induced apoptosis in breast cancer cells. Cell Cycle. 2010 Mar 15; 9(6):1122-30. PMID: 20237430.
      Citations: 15     Fields:    Translation:HumansCells
    66. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010 Feb 15; 16(4):1179-90. PMID: 20145171; PMCID: PMC2822889.
      Citations: 24     Fields:    Translation:HumansCells
    67. Mull BB, Cox J, Bui T, Keyomarsi K. Post-translational modification and stability of low molecular weight cyclin E. Oncogene. 2009 Sep 03; 28(35):3167-76. PMID: 19561641.
      Citations: 6     Fields:    Translation:HumansCells
    68. Agarwal R, Gonzalez-Angulo AM, Myhre S, Carey M, Lee JS, Overgaard J, Alsner J, Stemke-Hale K, Lluch A, Neve RM, Kuo WL, Sorlie T, Sahin A, Valero V, Keyomarsi K, Gray JW, Borresen-Dale AL, Mills GB, Hennessy BT. Integrative analysis of cyclin protein levels identifies cyclin b1 as a classifier and predictor of outcomes in breast cancer. Clin Cancer Res. 2009 Jun 01; 15(11):3654-62. PMID: 19470724; PMCID: PMC2887710.
      Citations: 67     Fields:    Translation:HumansCells
    69. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi SE, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, Haffty B, Hewitt SM, Krahe R, Killary AM. DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med. 2009 May 26; 6(5):e1000068. PMID: 19536326; PMCID: PMC2673042.
      Citations: 23     Fields:    Translation:HumansCells
    70. Wingate H, Puskas A, Duong M, Bui T, Richardson D, Liu Y, Tucker SL, Van Pelt C, Meijer L, Hunt K, Keyomarsi K. Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle. 2009 Apr 01; 8(7):1062-8. PMID: 19305161; PMCID: PMC2692060.
      Citations: 28     Fields:    Translation:Humans
    71. Delk NA, Hunt KK, Keyomarsi K. Altered subcellular localization of tumor-specific cyclin E isoforms affects cyclin-dependent kinase 2 complex formation and proteasomal regulation. Cancer Res. 2009 Apr 01; 69(7):2817-25. PMID: 19318554; PMCID: PMC2669888.
      Citations: 29     Fields:    Translation:HumansCells
    72. Fearmonti RM, Keyomarsi K, Hunt KK. Biomarkers in neoadjuvant trials. Cancer Treat Res. 2009; 147:1-36. PMID: 21461824.
      Citations:    Fields:    Translation:Humans
    73. Shaye A, Sahin A, Hao Q, Hunt K, Keyomarsi K, Bedrosian I. Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat. 2009 Jun; 115(3):651-9. PMID: 19107593; PMCID: PMC6130890.
      Citations: 21     Fields:    Translation:HumansCells
    74. Keyomarsi K. A novel MCM-2 fragment with potential biological function in senescence. Cell Cycle. 2008 Nov 15; 7(22):3480. PMID: 19001846.
      Citations:    Fields:    Translation:Humans
    75. Lambert LA, Qiao N, Hunt KK, Lambert DH, Mills GB, Meijer L, Keyomarsi K. Autophagy: a novel mechanism of synergistic cytotoxicity between doxorubicin and roscovitine in a sarcoma model. Cancer Res. 2008 Oct 01; 68(19):7966-74. PMID: 18829554; PMCID: PMC2561224.
      Citations: 44     Fields:    Translation:HumansCells
    76. Javanmoghadam-Kamrani S, Keyomarsi K. Synchronization of the cell cycle using lovastatin. Cell Cycle. 2008 Aug; 7(15):2434-40. PMID: 18677105.
      Citations: 34     Fields:    Translation:HumansAnimalsCells
    77. Yokota T, Bui T, Liu Y, Yi M, Hunt KK, Keyomarsi K. Differential regulation of elafin in normal and tumor-derived mammary epithelial cells is mediated by CCAAT/enhancer binding protein beta. Cancer Res. 2007 Dec 01; 67(23):11272-83. PMID: 18056453.
      Citations: 12     Fields:    Translation:HumansCells
    78. von Holzen U, Pataer A, Raju U, Bocangel D, Vorburger SA, Liu Y, Lu X, Roth JA, Aggarwal BB, Barber GN, Keyomarsi K, Hunt KK, Swisher SG. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Clin Cancer Res. 2007 Oct 15; 13(20):6032-9. PMID: 17947465.
      Citations: 12     Fields:    Translation:AnimalsCells
    79. Bedrosian I, Lee C, Tucker SL, Palla SL, Lu K, Keyomarsi K. Cyclin E-associated kinase activity predicts response to platinum-based chemotherapy. Clin Cancer Res. 2007 Aug 15; 13(16):4800-6. PMID: 17699858.
      Citations: 7     Fields:    Translation:Humans
    80. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 2007 Aug 01; 67(15):7212-22. PMID: 17671189.
      Citations: 38     Fields:    Translation:HumansAnimalsCells
    81. Lambert L, Keyomarsi K. Cell cycle deregulation in breast cancer: insurmountable chemoresistance or Achilles' heel? Adv Exp Med Biol. 2007; 608:52-69. PMID: 17993232.
      Citations: 2     Fields:    Translation:Humans
    82. Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol. 2006 Dec; 209(3):686-94. PMID: 17001684.
      Citations: 7     Fields:    Translation:HumansAnimals
    83. McGahren-Murray M, Terry NH, Keyomarsi K. The differential staurosporine-mediated G1 arrest in normal versus tumor cells is dependent on the retinoblastoma protein. Cancer Res. 2006 Oct 01; 66(19):9744-53. PMID: 17018634.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    84. Le XF, Bedrosian I, Mao W, Murray M, Lu Z, Keyomarsi K, Lee MH, Zhao J, Bast RC. Anti-HER2 antibody trastuzumab inhibits CDK2-mediated NPAT and histone H4 expression via the PI3K pathway. Cell Cycle. 2006 Aug; 5(15):1654-61. PMID: 16861913.
      Citations: 12     Fields:    Translation:HumansCells
    85. Efuet ET, Keyomarsi K. Farnesyl and geranylgeranyl transferase inhibitors induce G1 arrest by targeting the proteasome. Cancer Res. 2006 Jan 15; 66(2):1040-51. PMID: 16424040.
      Citations: 16     Fields:    Translation:HumansCells
    86. Tez M, Tez S. Clinical outcome of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry. Cancer. 2005 Oct 15; 104(8):1779-80; author reply 1780. PMID: 16104028.
      Citations:    Fields:    Translation:Humans
    87. Eder AM, Sui X, Rosen DG, Nolden LK, Cheng KW, Lahad JP, Kango-Singh M, Lu KH, Warneke CL, Atkinson EN, Bedrosian I, Keyomarsi K, Kuo WL, Gray JW, Yin JC, Liu J, Halder G, Mills GB. Atypical PKCiota contributes to poor prognosis through loss of apical-basal polarity and cyclin E overexpression in ovarian cancer. Proc Natl Acad Sci U S A. 2005 Aug 30; 102(35):12519-24. PMID: 16116079; PMCID: PMC1188258.
      Citations: 103     Fields:    Translation:HumansAnimals
    88. Hunt KK, Keyomarsi K. Cyclin E as a prognostic and predictive marker in breast cancer. Semin Cancer Biol. 2005 Aug; 15(4):319-26. PMID: 16043362.
      Citations: 28     Fields:    Translation:Humans
    89. Wingate H, Zhang N, McGarhen MJ, Bedrosian I, Harper JW, Keyomarsi K. The tumor-specific hyperactive forms of cyclin E are resistant to inhibition by p21 and p27. J Biol Chem. 2005 Apr 15; 280(15):15148-57. PMID: 15708847.
      Citations: 39     Fields:    Translation:HumansAnimalsCells
    90. Bales E, Mills L, Milam N, McGahren-Murray M, Bandyopadhyay D, Chen D, Reed JA, Timchenko N, van den Oord JJ, Bar-Eli M, Keyomarsi K, Medrano EE. The low molecular weight cyclin E isoforms augment angiogenesis and metastasis of human melanoma cells in vivo. Cancer Res. 2005 Feb 01; 65(3):692-7. PMID: 15705861.
      Citations: 30     Fields:    Translation:HumansAnimals
    91. Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004 Jul 15; 59(4):928-42. PMID: 15234026.
      Citations: 383     Fields:    Translation:Cells
    92. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res. 2004; 6(5):188-91. PMID: 15318923; PMCID: PMC549170.
      Citations: 10     Fields:    Translation:AnimalsCells
    93. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004 May 01; 64(9):3198-208. PMID: 15126360.
      Citations: 65     Fields:    Translation:HumansAnimalsCells
    94. Bedrosian I, Lu KH, Verschraegen C, Keyomarsi K. Cyclin E deregulation alters the biologic properties of ovarian cancer cells. Oncogene. 2004 Apr 08; 23(15):2648-57. PMID: 15007381.
      Citations: 33     Fields:    Translation:HumansCells
    95. Harwell RM, Mull BB, Porter DC, Keyomarsi K. Activation of cyclin-dependent kinase 2 by full length and low molecular weight forms of cyclin E in breast cancer cells. J Biol Chem. 2004 Mar 26; 279(13):12695-705. PMID: 14701826.
      Citations: 8     Fields:    Translation:HumansAnimalsCells
    96. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6. PMID: 12963845.
      Citations: 18     Fields:    Translation:HumansAnimalsCells
    97. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S38-47. PMID: 14508079.
      Citations: 30     Fields:    Translation:HumansCells
    98. Rabinowitz I. Cyclin E in breast cancer. N Engl J Med. 2003 Mar 13; 348(11):1063-4; author reply 1063-4. PMID: 12638587.
      Citations:    Fields:    Translation:Humans
    99. Keyomarsi K, Tucker SL, Bedrosian I. Cyclin E is a more powerful predictor of breast cancer outcome than proliferation. Nat Med. 2003 Feb; 9(2):152. PMID: 12563321.
      Citations: 10     Fields:    
    100. Keyomarsi K, Pardee AB. Selective protection of normal proliferating cells against the toxic effects of chemotherapeutic agents. Prog Cell Cycle Res. 2003; 5:527-32. PMID: 14593747.
      Citations: 9     Fields:    Translation:HumansAnimals
    101. Keyomarsi K, Tucker SL, Buchholz TA, Callister M, Ding Y, Hortobagyi GN, Bedrosian I, Knickerbocker C, Toyofuku W, Lowe M, Herliczek TW, Bacus SS. Cyclin E and survival in patients with breast cancer. N Engl J Med. 2002 Nov 14; 347(20):1566-75. PMID: 12432043.
      Citations: 181     Fields:    Translation:Humans
    102. Blagosklonny MV, Campisi J, Keyomarsi K, Medrano EE. No restriction points in life and science. Cell Cycle. 2002 Mar-Apr; 1(2):100-2. PMID: 12429915.
      Citations: 2     Fields:    Translation:HumansAnimalsCells
    103. Porter DC, Zhang N, Danes C, McGahren MJ, Harwell RM, Faruki S, Keyomarsi K. Tumor-specific proteolytic processing of cyclin E generates hyperactive lower-molecular-weight forms. Mol Cell Biol. 2001 Sep; 21(18):6254-69. PMID: 11509668; PMCID: PMC87349.
      Citations: 68     Fields:    Translation:HumansCells
    104. Koepp DM, Schaefer LK, Ye X, Keyomarsi K, Chu C, Harper JW, Elledge SJ. Phosphorylation-dependent ubiquitination of cyclin E by the SCFFbw7 ubiquitin ligase. Science. 2001 Oct 05; 294(5540):173-7. PMID: 11533444.
      Citations: 377     Fields:    Translation:HumansAnimalsCells
    105. Bacus SS, Gudkov AV, Lowe M, Lyass L, Yung Y, Komarov AP, Keyomarsi K, Yarden Y, Seger R. Taxol-induced apoptosis depends on MAP kinase pathways (ERK and p38) and is independent of p53. Oncogene. 2001 Jan 11; 20(2):147-55. PMID: 11313944.
      Citations: 110     Fields:    Translation:HumansAnimalsCells
    106. Chen X, Lowe M, Herliczek T, Hall MJ, Danes C, Lawrence DA, Keyomarsi K. Protection of normal proliferating cells against chemotherapy by staurosporine-mediated, selective, and reversible G(1) arrest. J Natl Cancer Inst. 2000 Dec 20; 92(24):1999-2008. PMID: 11121462.
      Citations: 12     Fields:    Translation:HumansCells
    107. Porter DC, Keyomarsi K. Novel splice variants of cyclin E with altered substrate specificity. Nucleic Acids Res. 2000 Dec 01; 28(23):E101. PMID: 11095697; PMCID: PMC115185.
      Citations: 19     Fields:    Translation:HumansCells
    108. Chen X, Danes C, Lowe M, Herliczek TW, Keyomarsi K. Activation of the estrogen-signaling pathway by p21(WAF1/CIP1) in estrogen receptor-negative breast cancer cells. J Natl Cancer Inst. 2000 Sep 06; 92(17):1403-13. PMID: 10974076.
      Citations: 11     Fields:    Translation:HumansCells
    109. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol. 2000 Aug 30; 166(2):156-69. PMID: 11203301.
      Citations: 7     Fields:    Translation:HumansCells
    110. Robertson KD, Keyomarsi K, Gonzales FA, Velicescu M, Jones PA. Differential mRNA expression of the human DNA methyltransferases (DNMTs) 1, 3a and 3b during the G(0)/G(1) to S phase transition in normal and tumor cells. Nucleic Acids Res. 2000 May 15; 28(10):2108-13. PMID: 10773079; PMCID: PMC105379.
      Citations: 70     Fields:    Translation:HumansCells
    111. Fasco MJ, Keyomarsi K, Arcaro KF, Gierthy JF. Expression of an estrogen receptor alpha variant protein in cell lines and tumors. Mol Cell Endocrinol. 2000 Apr 25; 162(1-2):167-80. PMID: 10854710.
      Citations: 4     Fields:    Translation:HumansCells
    112. Harwell RM, Porter DC, Danes C, Keyomarsi K. Processing of cyclin E differs between normal and tumor breast cells. Cancer Res. 2000 Jan 15; 60(2):481-9. PMID: 10667604.
      Citations: 29     Fields:    Translation:HumansCells
    113. Rao S, Gray-Bablin J, Herliczek TW, Keyomarsi K. The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway. Exp Cell Res. 1999 Oct 10; 252(1):211-23. PMID: 10502413.
      Citations: 4     Fields:    Translation:HumansCells
    114. Chen X, Lowe M, Keyomarsi K. UCN-01-mediated G1 arrest in normal but not tumor breast cells is pRb-dependent and p53-independent. Oncogene. 1999 Oct 07; 18(41):5691-702. PMID: 10577141.
      Citations: 1     Fields:    Translation:HumansCells
    115. Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G1 arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999 Jul 06; 96(14):7797-802. PMID: 10393901; PMCID: PMC22141.
      Citations: 113     Fields:    Translation:HumansCells
    116. Rao S, Lowe M, Herliczek TW, Keyomarsi K. Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. Oncogene. 1998 Nov 05; 17(18):2393-402. PMID: 9811471.
      Citations: 52     Fields:    Translation:HumansCells
    117. Gray-Bablin J, Rao S, Keyomarsi K. Lovastatin induction of cyclin-dependent kinase inhibitors in human breast cells occurs in a cell cycle-independent fashion. Cancer Res. 1997 Feb 15; 57(4):604-9. PMID: 9044834.
      Citations: 17     Fields:    Translation:HumansCells
    118. Stover PJ, Chen LH, Suh JR, Stover DM, Keyomarsi K, Shane B. Molecular cloning, characterization, and regulation of the human mitochondrial serine hydroxymethyltransferase gene. J Biol Chem. 1997 Jan 17; 272(3):1842-8. PMID: 8999870.
      Citations: 47     Fields:    Translation:HumansAnimalsCells
    119. Keyomarsi K, Herliczek TW. The role of cyclin E in cell proliferation, development and cancer. Prog Cell Cycle Res. 1997; 3:171-91. PMID: 9552414.
      Citations: 35     Fields:    Translation:HumansAnimalsCells
    120. Gray-Bablin J, Zalvide J, Fox MP, Knickerbocker CJ, DeCaprio JA, Keyomarsi K. Cyclin E, a redundant cyclin in breast cancer. Proc Natl Acad Sci U S A. 1996 Dec 24; 93(26):15215-20. PMID: 8986790; PMCID: PMC26383.
      Citations: 30     Fields:    Translation:HumansAnimalsCells
    121. Huang Z, Fasco MJ, Figge HL, Keyomarsi K, Kaminsky LS. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab Dispos. 1996 Aug; 24(8):899-905. PMID: 8869826.
      Citations: 38     Fields:    Translation:Humans
    122. Bacus SS, Yarden Y, Oren M, Chin DM, Lyass L, Zelnick CR, Kazarov A, Toyofuku W, Gray-Bablin J, Beerli RR, Hynes NE, Nikiforov M, Haffner R, Gudkov A, Keyomarsi K. Neu differentiation factor (Heregulin) activates a p53-dependent pathway in cancer cells. Oncogene. 1996 Jun 20; 12(12):2535-47. PMID: 8700512.
      Citations: 12     Fields:    Translation:HumansCells
    123. Dou QP, Pardee AB, Keyomarsi K. Cyclin E -- a better prognostic marker for breast cancer than cyclin D? Nat Med. 1996 Mar; 2(3):254. PMID: 8612208.
      Citations: 6     Fields:    Translation:Humans
    124. Keyomarsi K, Conte D, Toyofuku W, Fox MP. Deregulation of cyclin E in breast cancer. Oncogene. 1995 Sep 07; 11(5):941-50. PMID: 7675453.
      Citations: 67     Fields:    Translation:HumansCells
    125. Harper JW, Elledge SJ, Keyomarsi K, Dynlacht B, Tsai LH, Zhang P, Dobrowolski S, Bai C, Connell-Crowley L, Swindell E, et al. Inhibition of cyclin-dependent kinases by p21. Mol Biol Cell. 1995 Apr; 6(4):387-400. PMID: 7626805; PMCID: PMC301199.
      Citations: 275     Fields:    Translation:HumansCells
    126. Rosowsky A, Bader H, Wright JE, Keyomarsi K, Matherly LH. Synthesis and biological activity of N omega-hemiphthaloyl-alpha,omega- diaminoalkanoic acid analogues of aminopterin and 3',5-dichloroaminopterin. J Med Chem. 1994 Jul 08; 37(14):2167-74. PMID: 8035423.
      Citations: 9     Fields:    Translation:HumansAnimalsCells
    127. Keyomarsi K, O'Leary N, Molnar G, Lees E, Fingert HJ, Pardee AB. Cyclin E, a potential prognostic marker for breast cancer. Cancer Res. 1994 Jan 15; 54(2):380-5. PMID: 7903908.
      Citations: 85     Fields:    Translation:Humans
    128. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993 Nov 19; 75(4):805-16. PMID: 8242751.
      Citations: 1661     Fields:    Translation:HumansCells
    129. Keyomarsi K, Samet J, Molnar G, Pardee AB. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme. J Biol Chem. 1993 Jul 15; 268(20):15142-9. PMID: 8325888.
      Citations: 17     Fields:    Translation:HumansCells
    130. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A. 1993 Feb 01; 90(3):1112-6. PMID: 8430082; PMCID: PMC45821.
      Citations: 123     Fields:    Translation:HumansCells
    131. Liang P, Averboukh L, Keyomarsi K, Sager R, Pardee AB. Differential display and cloning of messenger RNAs from human breast cancer versus mammary epithelial cells. Cancer Res. 1992 Dec 15; 52(24):6966-8. PMID: 1458489.
      Citations: 52     Fields:    Translation:HumansCells
    132. Motokura T, Keyomarsi K, Kronenberg HM, Arnold A. Cloning and characterization of human cyclin D3, a cDNA closely related in sequence to the PRAD1/cyclin D1 proto-oncogene. J Biol Chem. 1992 Oct 05; 267(28):20412-5. PMID: 1383201.
      Citations: 40     Fields:    Translation:HumansCells
    133. Lee SW, Tomasetto C, Paul D, Keyomarsi K, Sager R. Transcriptional downregulation of gap-junction proteins blocks junctional communication in human mammary tumor cell lines. J Cell Biol. 1992 Sep; 118(5):1213-21. PMID: 1324944; PMCID: PMC2289599.
      Citations: 53     Fields:    Translation:HumansAnimalsCells
    134. Pardee AB, Keyomarsi K. Modification of cell proliferation with inhibitors. Curr Opin Cell Biol. 1992 Apr; 4(2):186-91. PMID: 1376129.
      Citations: 7     Fields:    Translation:HumansAnimalsCells
    135. Lee SW, Tomasetto C, Swisshelm K, Keyomarsi K, Sager R. Down-regulation of a member of the S100 gene family in mammary carcinoma cells and reexpression by azadeoxycytidine treatment. Proc Natl Acad Sci U S A. 1992 Mar 15; 89(6):2504-8. PMID: 1372446; PMCID: PMC48687.
      Citations: 39     Fields:    Translation:HumansCells
    136. Keyomarsi K, Sandoval L, Band V, Pardee AB. Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res. 1991 Jul 01; 51(13):3602-9. PMID: 1711413.
      Citations: 137     Fields:    Translation:HumansAnimalsCells
    137. Fridovich-Keil JL, Hansen LJ, Keyomarsi K, Pardee AB. Progression through the cell cycle: an overview. Am Rev Respir Dis. 1990 Dec; 142(6 Pt 2):S3-6. PMID: 2252273.
      Citations: 1     Fields:    Translation:HumansAnimals
    138. Keyomarsi K, Moran RG. Quinazoline folate analogs inhibit the catalytic activity of thymidylate synthase but allow binding of 5-fluorodeoxyuridylate. J Biol Chem. 1990 Nov 05; 265(31):19163-9. PMID: 2146271.
      Citations: 1     Fields:    Translation:AnimalsCells
    139. Geller AI, Keyomarsi K, Bryan J, Pardee AB. An efficient deletion mutant packaging system for defective herpes simplex virus vectors: potential applications to human gene therapy and neuronal physiology. Proc Natl Acad Sci U S A. 1990 Nov; 87(22):8950-4. PMID: 2174168; PMCID: PMC55078.
      Citations: 23     Fields:    Translation:AnimalsCells
    140. Keyomarsi K, Moran RG. Mechanism of the cytotoxic synergism of fluoropyrimidines and folinic acid in mouse leukemic cells. J Biol Chem. 1988 Oct 05; 263(28):14402-9. PMID: 2971656.
      Citations: 15     Fields:    Translation:Animals
    141. Moran RG, Keyomarsi K, Patel R. Tumor cell responses to inhibition of thymidylate synthase. Adv Exp Med Biol. 1988; 244:71-83. PMID: 2977717.
      Citations:    Fields:    Translation:HumansAnimalsCells
    142. Mahnovski V, Cheng MH, Lipsey AI, Keyomarsi K. Drugs in blood donors. Clin Chem. 1987 Jan; 33(1):189. PMID: 3802478.
      Citations:    Fields:    Translation:Humans
    143. Moran RG, Keyomarsi K. Biochemical rationale for the synergism of 5-fluorouracil and folinic acid. NCI Monogr. 1987; (5):159-63. PMID: 2963229.
      Citations: 9     Fields:    Translation:AnimalsCells
    144. Keyomarsi K, Moran RG. Folinic acid augmentation of the effects of fluoropyrimidines on murine and human leukemic cells. Cancer Res. 1986 Oct; 46(10):5229-35. PMID: 2944577.
      Citations: 27     Fields:    Translation:HumansAnimalsCells
    145. Moran RG, Keyomarsi K, Colman PD. Preparation of (6S)-5-formyltetrahydrofolate labeled at high specific activity with 14C and 3H. Methods Enzymol. 1986; 122:309-12. PMID: 3517564.
      Citations: 2     Fields:    
    146. PAF-Wnt signaling-induced cell plasticity is required for maintenance of breast cancer cell stemness. Nature Communications. 7.
    147. Estrogen receptor alpha is cell cycle-regulated and regulates the cell cycle in a ligand-dependent fashion. Cell Cycle. 1-12.
    148. Biomarkers in neoadjuvant trials. 125-160.
    149. Erratum. Molecular and Cellular Endocrinology. 166:155-169.
    150. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Research. 16.
    151. Cyclin e amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Breast Diseases. 22:266-267.
    152. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 34:3556-3567.
    153. Cyclin e associates with the lipogenic enzyme ATP-citrate lyase to enable malignant growth of breast cancer cells. Cancer Research. 76:2406-2418.
    154. AXL inhibition suppresses the DNA damage response and sensitizes cells to PARP inhibition in multiple cancers. Molecular Cancer Research. 15:45-58.
    155. A phase 1 study with dose expansion of the CDK inhibitor dinaciclib (SCH 727965) in combination with epirubicin in patients with metastatic triple negative breast cancer. Investigational New Drugs.
    156. Synchronization of mammalian cells by Lovastatin. Methods in Cell Science. 18:109-114.
    157. Targeting the Cell Cycle in Breast Cancer. Breast Diseases. 27:256-260.
    158. Erratum to. Breast Cancer Research. 17.
    159. Understanding the Biology of Cancer. 101-122.
    160. PKCiota promotes ovarian tumor progression through deregulation of cyclin E. Oncogene.
    161. Sequential combination therapy of CDK inhibition and doxorubicin is synthetically lethal in p53-mutant Triple-negative breast cancer. Molecular Cancer Therapeutics. 15:593-607.
    KEYOMARSI's Networks
    Click the
    buttons for more information and interactive visualizations!
    Concepts (558)
    Co-Authors (90)
    Similar People (60)
    Same Department Expand Description